VIRACEPT
LOE Approachingnelfinavir mesylate
NDAORALTABLETPriority Review
Approved
Mar 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIRACEPT (nelfinavir mesylate) is an oral protease inhibitor approved in 1997 for HIV infection and related opportunistic infections including MAC, tuberculosis, and lipodystrophy. It works by inhibiting HIV protease, preventing viral replication in infected cells.
$0.9MPart D
LOE ApproachingDeclining
Minimal commercial activity with only $909K in Part D spending (2023) suggests significantly reduced market presence as LOE approaches, indicating small team size and limited career growth opportunity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
Started Mar 2017
36 enrolled
Recurrent Kaposi SarcomaSkin Kaposi Sarcoma
Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy
Started Mar 2006
16 enrolled
HIV Infection
Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen
Started Aug 2002
179 enrolled
Human Immunodeficiency Virus
Career Relevance
VIRACEPT offers very limited career opportunity with zero linked job openings and minimal commercial traction ($909K annual Part D spending). Working on this product means supporting a legacy asset in decline rather than driving growth or innovation.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.